RxDoctor Payments DataLook up a doctor →

Katy Crowe, MD

Family Medicine · Wilmington, DENPI 1962662122

Payments from drug & device makers

$12,231in general payments, 2019–2025

Across 722 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AbbVie$2K
  • Amgen$1K
  • Novo Nordisk$856
  • Pfizer$765
  • Astellas Pharma US Inc$651
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$12,212100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC97$1,680
AbbVie(2 entities)93$1,677
Amgen72$1,097
Novo Nordisk61$856
Pfizer54$765
Astellas Pharma US Inc37$651
GSK37$635
AstraZeneca31$545
Kowa Pharmaceuticals America, Inc.26$360
Abbott21$356
Merck22$340
Teva Pharmaceuticals USA, Inc.19$321
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$275
Biocryst US Sales Co., LLC7$274
Johnson & Johnson13$210
Paratek Pharmaceuticals, Inc.9$190
Boehringer Ingelheim13$184
Dexcom, Inc.4$152
CSL Behring6$150
Sanofi-aventis U.S. LLC7$146
Sumitomo Pharma America, Inc.6$124
Exact Sciences5$105
Nestle Healthcare Nutrition Inc.6$102
Seqirus USA Inc4$68
Takeda Pharmaceuticals U.S.A., Inc.3$64
Amarin Pharma, Inc.4$62
Biohaven Pharmaceutical Holding Company Ltd.3$61
Biohaven Pharmaceuticals, Inc.4$57
Myriad Women's Health, Inc.1$56
Novartis4$53
Vanda Pharmaceuticals Inc.2$39
Idorsia Pharmaceuticals US Inc2$39
Vivus LLC2$36
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$33
Sanofi Pasteur Inc.2$32
Eisai Inc.2$30
Shield Therapeutics Inc2$28
Phathom Pharmaceuticals, Inc.2$27
Aurinia Pharma U.S., Inc.1$27
Daiichi Sankyo Inc.1$26
Neurocrine Biosciences, Inc.1$23
Adlon Therapeutics L.p.1$22
Medtronic1$21
Heartflow, Inc.1$21
Bayer1$21
Otsuka America Pharmaceutical, Inc.1$20
E.r. Squibb & Sons, L.L.C.1$18
IBSA Pharma Inc.1$18
Scilex Pharmaceuticals Inc.1$18
Genentech USA, Inc.1$17
Otsuka Pharmaceutical Development & Commercialization, Inc.1$17
Shire North American Group Inc1$16
Appliedvr Inc1$14
Digestive Care, Inc.1$14
Boston Scientific1$13
Lundbeck LLC1$13
Acarix USA Inc.1$11

How this compares

$12,231 in reported general payments places this provider in the 95th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$146,167
Medicare patients
252
Services billed
3,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide77$84,204
OzempicSemaglutide51$72,792
JardianceEmpagliflozin34$48,224
FarxigaDapagliflozin Propanediol25$29,899
TrulicityDulaglutide19$28,484
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$28,130
Repatha SureclickEvolocumab33$27,042
MyrbetriqMirabegron26$24,534
JanuviaSitagliptin Phosphate12$17,938
XareltoRivaroxaban15$16,832
EliquisApixaban17$13,611
Rosuvastatin Calcium532$12,724
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,154
QuviviqDaridorexant Hcl12$5,861
ArexvyRsvpref3 Antigen/As01e/Pf18$5,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,680$112,68796 claims
Novo NordiskOzempic$856$72,79251 claims
Boehringer IngelheimJardiance$184$48,22434 claims
GSKTrelegy Ellipta, Arexvy, Arnuity Ellipta$635$37,19148 claims
AstraZenecaFarxiga$545$29,89925 claims
Astellas Pharma US IncMyrbetriq$651$24,53426 claims
MerckJanuvia$340$17,93812 claims
Johnson & JohnsonXarelto$210$16,83215 claims
PfizerEliquis$765$13,61117 claims
Idorsia Pharmaceuticals US IncQuviviq$39$5,86112 claims
AbbVieSynthroid$1,677$4,68948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →